The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|March 23, 2006
PHARMALINKFHI RENEWS LICENSE AGREEMENT WITH PHASE FORWARD
Company Relies on Phase Forward's InForm EDC Solution to Accelerate Clinical Data Collection and Analysis
Advertisement
Waltham, Mass. – March 23, 2006 – Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced PharmaLinkFHI (PharmaLink), a leading electronic clinical research organization (eCRO), has signed a three-year license agreement to extend its use of Phase Forward's InForm™ Web-based solution for electronic data capture (EDC). A longtime strategic partner, PharmaLink plans to continue to leverage Phase Forward's InForm as one of its primary EDC tools.
With the InForm solution, PharmaLink can help its clients quickly and efficiently access, analyze and report critical clinical data. Because InForm offers enterprise-level scalability - to thousands of sites and tens of thousands of patients - and extensive functionality in an intuitive user interface, clinical development staff can do more faster and with greater accuracy.
"As the leading eCRO conducting all of our trials in EDC, we realized InForm's benefits long ago and have shared many successful implementations with Phase Forward during our strong, six-year partnership," said Richard Staub, president and chief operating officer, PharmaLink. "Because of the increased efficiency it affords, we integrated InForm with our Web-based clinical trial management and reporting system (CTMS), InfoLink. By leveraging the data visibility afforded by our technology platform, combined with our high efficiency clinical processes, we've reduced the time from Last Patient/Last Visit to database lock to between three to eight working days. In addition to its functionality, Phase Forward's worldwide experience will be particularly critical to PharmaLink as we anticipate future global engagements."
"As a firm that's focused on real-time clinical trial management, PharmaLink is at the vanguard of technology adoption," said Bob Weiler, president and chief executive officer, Phase Forward. "The company has pioneered best practices to ensure quality and provide high levels of visibility into the clinical trial process. We are pleased to be working with such a committed partner."
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5